HLA-A and neoplasm: For example, the engineered αβ T cells, which expressed Vγ5Vδ1+ TCRs, could be activated by HLA-A*24:02+ tumor cells and significantly decreased the tumor burden and enhanced survival rate of HLA-A*24:02+ tumor-bearing mice (25).